Present results and previous data demonstrate that FXR exerts an anti-inflammatory activity in rodent models of colitis [18] while promoting a less activated phenotype in the adipose tissue [39], suggesting a potential therapeutic role for ligands of this nuclear receptor in the treatment of inflammation-driven activation of adipose tissue in Crohn's disease. Here, NR1H4 is linked to Crohn disease.